Pharmacogenetics and Genomics

Papers
(The median citation count of Pharmacogenetics and Genomics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target16
GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes13
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation12
Establishing national reference materials for genetic testing of cytochrome P45012
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients12
The prevalence of pharmacogenetic testing in the United States11
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the11
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation10
The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia9
Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort9
Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis8
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy8
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort8
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) June 12-13, 2023 Memphis, TN, USA7
Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy6
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer6
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics6
Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis6
PharmGKB summary: disulfiram pathway6
Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines6
Genome-wide DNA methylation profile of peripheral blood lymphocytes from subjects with nonsteroidal anti-inflammatory drug-induced respiratory diseases6
Mouse nerve growth factor suppresses neuronal apoptosis in valproic acid-induced autism spectrum disorder rats by regulating the phosphoinositide-3-kinase/serine/threonine kinase signaling pathway4
Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis4
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens4
HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation4
Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation4
Updated analysis of the pharmacogenomics of pediatric bronchodilator response4
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs4
Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension3
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects3
Associations of ADH1B and ALDH2 genotypes and alcohol flushing with drinking history, withdrawal symptoms, and ICD-10 criteria in Japanese alcohol-dependent men3
MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway3
Identification of potential druggable targets of cell cycle with small-molecule inhibitors in oral squamous cell carcinoma3
Association of ATP8B3 gene polymorphisms with aspirin-exacerbated respiratory disease in asthmatics3
Association of genetic variation with irinotecan infusion reactions and severe toxicity2
Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype2
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs2
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis2
Microsampling with dried blood spots and mass spectrometry enables PK/PD profiling of responses to praziquantel in a Schistosoma haematobium–exposed Zimbabwean population2
Metabolic effects of heterocyclic amines on insulin‑induced AKT phosphorylation and gluconeogenic gene expression are modified by N-acetyltransferase 2 genetic polymorphism2
Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated?2
Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients2
Diversity of oncopharmacogenetic profile within Spanish population2
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients2
Evaluation of tagged SNPs for HLA markers, HLA-B*15:02 and HLA-A*31:01, that are used to predict carbamazepine induced adverse effects: Erratum2
PharmGKB summary: acyclovir/ganciclovir pathway2
Cytochrome P4503A4 gene polymorphisms guide safe sufentanil analgesic doses in pregnant Chinese mothers: a multicenter, randomized, prospective study2
Pan-cancer single-cell landscape of drug-metabolizing enzyme genes2
Implementation of pharmacogenomics into inpatient general medicine1
Bone marrow mesenchymal stem cell-derived exosomes carrying E3 ubiquitin ligase ITCH attenuated cardiomyocyte apoptosis by mediating apoptosis signal-regulated kinase-11
Exome-wide association study identifies a phosphatidylethanolamine-binding protein 4 variant associated with idiopathic pulmonary fibrosis risk in Koreans1
Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature1
Pregnane X receptor gene variant rs7643645 and total mortality in subjects with nonalcoholic fatty liver disease1
Evaluation of ADRB2 and OATP2A1 genetic polymorphisms in Indian patients with primary open-angle glaucoma1
Pharmacogenetic analysis of canonical versus noncanonical pathway of NF-kB in Crohn’s disease patients under anti-tumor necrosis factor-α treatment1
Inferring germline pharmacogenomics from tumor transcriptome1
Cancer genomic medicine in Japan and the roles of pharmacists1
Association between opioid and dopamine receptor gene polymorphisms OPRM1rs1799971, DAT VNTR9-10 repeat allele, DRD1 rs4532 and DRD2 rs1799732 and alcohol dependence: an ethnicity oriented meta-analys1
Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents1
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV1
Prevalence of CYP2D6 structural variation in large retrospective study1
Attitudes on pharmacogenomic results as secondary findings among medical geneticists1
Impact of UGT1A4 and UGT2B7 polymorphisms on lamotrigine plasma concentration in patients with bipolar disorder1
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms1
Cisplatin-induced ototoxicity: a novel approach to an ancient problem1
Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity1
Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients1
Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank1
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) September 23-25, 2024 at the Ohio State University in Columbus, Ohio, USA1
Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes1
‘Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation’ by Ali et al.1
Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen1
Development of an ARMS multiplex real-time PCR assay for the detection of HLA-B*13:01 genotype by detecting highly specific SNPs1
Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis1
Pharmacogenomic analysis of low-density lipoprotein receptor 3’ untranslated region genetic variants influencing rosuvastatin efficacy in Chinese dyslipidemia patients1
Association of the ACE and AGT gene polymorphisms with global disparities in COVID-19-related deaths1
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants1
0.96727395057678